Description
AMBLE · RESEARCH PRODUCT INFORMATION
Product overview
Hexarelin, also known as examorelin, is a synthetic growth-hormone-releasing hexapeptide investigated in ghrelin-receptor and endocrine research. The source discusses experimental cardiovascular and metabolic studies; these are research topics, not established uses for this vial.
For scientific research and development only. Intended for in-vitro laboratory work, not human or animal administration. Not for use as a medicine, diagnostic product, medical device, food, supplement or cosmetic. No dosing, injection or treatment instructions are provided.
Product specifications
| Quantity | 5 mg |
|---|---|
| Unit | 1 Vial |
| Physical Appearance | White powder |
| Salt form | Acetate |
| Supplier reference purity (not lot verification) | ≥99% |
| Sequence | His-2MeDTrp-Ala-Trp-DPhe-Lys-NH2 |
| Source-reported molecular mass (units not stated) | 887 |
| CAS NO. | 140703-51-1 |
| Source-listed laboratory solvents | NaCl / Sterile / Bacteriostatic water |
Product features
- Source-listed pack: 5 mg 1 Vial
- Source-listed presentation: White powder
These characteristics identify the supplier reference presentation. They are not independent testing or verification of the current Amble lot.
These are reference specifications reported on the corresponding Particle Peptides page, not independent analytical verification of an Amble lot. Confirm the received label, identity, formulation and batch documentation before laboratory use. Unlisted fields have not been invented.
Storage and handling
1. Research use and restrictions
For scientific research and development only. Intended for in-vitro laboratory work, not human or animal administration. Not for use as a medicine, diagnostic product, medical device, food, supplement or cosmetic. No dosing, injection or treatment instructions are provided.
Literature involving animals or clinical studies is background information only and does not authorize this product for those uses. Do not supply this material for human investigational use.
2. Peptides in transport
Follow the current product label and lot-specific transport documentation. A general supplier statement about transport stability is not a guarantee for every formulation, liquid, blend or Amble shipment. The source supplier lists shipping restrictions for: Canada, Croatia, Czech Republic, Estonia, Finland, Germany, Iceland, Ireland, Italy, Luxemburg, Norway, Romania, Serbia, South Africa, Sweden, Switzerland. This is the supplier’s published list, not a complete legal assessment or a replacement for Amble’s shipping policy.
3. Storage of lyophilized peptides
The supplier gives general guidance to protect lyophilized peptides from light and moisture. Storage temperature and expiry must follow the actual formulation and lot documentation. Do not treat a generic storage-duration table as validated shelf-life data for this Amble product.
4. Storage of reconstituted peptides
Solution stability depends on sequence, formulation, solvent and handling. Use product-specific stability documentation and laboratory procedures rather than assuming the same refrigerated life for all peptides. The supplier’s Ipamorelin stability discussion cannot be extrapolated to other products without supporting data.
5. Storage of peptide solutions
Avoid unnecessary freeze–thaw cycling and follow the documented conditions for the exact solution. This page does not establish a validated shelf life after preparation. The listed solvent information is a supplier reference, not a patient-use or injection protocol.
Overview of published research
The corresponding source page discusses the topics below. They describe areas of investigation, not proven customer benefits, treatment indications or evidence that this particular Amble batch has been tested.
- Growth-hormone secretagogue receptor signaling
- Cardiovascular responses in experimental models
- Lipid metabolism and muscle biology
Interpretation depends on the study design, experimental material and model. The presence of a publication in a supplier bibliography is not an independent verification of the supplier’s interpretation or a guarantee of safety or effectiveness. No clinical doses or administration protocols are reproduced here.
Quality and documentation
Source attribution: the specifications and bibliography below refer to Particle Peptides. Amble branding does not turn the supplier’s studies or documents into Amble batch certifications.
View the corresponding supplier product page
- Supplier safety data sheet (MSDS)
- Supplier COA/test document — not verification of the current Amble lot
Document links are retained as supplier references. Confirm lot matching, document authenticity and applicability before relying on them; this update does not independently verify those documents.
Bibliography listed by the supplier (13 entries)
Bibliographic entries are attributed to the source page. Individual citations have not all been independently validated; consult the original publications and distinguish primary studies from secondary reports.
- E. Agbo et al., “Modulation of PTEN by hexarelin attenuates coronary artery ligation-induced heart failure in rats,” Turk. J. Med. Sci., vol. 49, no. 3, May 2019. [PubMed]
- H. McDonald et al., “Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction,” Physiol. Rep., vol. 6, no. 9, p. e13699, 2018. [PubMed]
- X. Xu et al., “Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat,” Am. J. Physiol. Heart Circ. Physiol., vol. 303, no. 6, pp. H703-711, Sep. 2012. [PubMed]
- X. Zhang, L. Qu, L. Chen, and C. Chen, “Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats,” Physiol. Rep., vol. 6, no. 4, 2018. [PubMed]
- Y. Mao, T. Tokudome, I. Kishimoto, K. Otani, M. Miyazato, and K. Kangawa, “One dose of oral hexarelin protects chronic cardiac function after myocardial infarction,” Peptides, vol. 56, pp. 156–162, Jun. 2014. [PubMed]
- Y. Ma, L. Zhang, J. N. Edwards, B. S. Launikonis, and C. Chen, “Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium,” PloS One, vol. 7, no. 4, p. e35265, 2012. [PloS One]
- R. Mosa et al., “Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice,” Endocrinology, vol. 158, no. 10, pp. 3174–3187, 01 2017. [PubMed]
- G. Sirago et al., “Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia,” Sci. Rep., vol. 7, Oct. 2017. [nature.com]
- E. Conte et al., “Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia,” J. Cachexia Sarcopenia Muscle, vol. 8, no. 3, pp. 386–404, Jun. 2017. [PubMed]
- Torsello, Antonio & Bresciani, Elena & Tamiazzo, Laura & Bulgarelli, Ilaria & Caporali, Simona & Moulin, Aline & Fehrentz, jean-alain & Martinez, Jean & Perissoud, Daniel & Locatelli, Vittorio. (2008). Novel potent and selective non-peptide ligands of ghrelin receptor : characterization of endocrine and extraendocrine actions. [Research Gate]
- Yuanjie Mao, Takeshi Tokudome,1 and Ichiro Kishimoto, „The cardiovascular action of hexarelin,” [PubMed]
- Torsello, Antonio & Bresciani, Elena & Tamiazzo, Laura & Bulgarelli, Ilaria & Caporali, Simona & Moulin, Aline & Fehrentz, jean-alain & Martinez, Jean & Perissoud, Daniel & Locatelli, Vittorio. (2008). Novel potent and selective non-peptide ligands of ghrelin receptor : characterization of endocrine and extraendocrine actions. [Research Gate]
- Yuanjie Mao, Takeshi Tokudome, and Ichiro Kishimoto, „The cardiovascular action of hexarelin.” [PubMed]
Product questions and answers
What is Hexarelin 5mg?
Hexarelin, also known as examorelin, is a synthetic growth-hormone-releasing hexapeptide investigated in ghrelin-receptor and endocrine research. The source discusses experimental cardiovascular and metabolic studies; these are research topics, not established uses for this vial.
What quantity is listed for Hexarelin 5mg?
The corresponding supplier reference lists 5 mg 1 Vial. This applies to the stated presentation only; other strengths and quantities are not included.
Which identity or formulation details matter for Hexarelin 5mg?
The supplier provides 9 reference specification fields for this listing. Those fields and source documents are not an independent Amble batch certificate.
Does the linked documentation certify this Amble batch?
No Amble-lot certification is established by a supplier webpage or an unmatched COA. Confirm the laboratory report, exact batch number, identity and formulation before relying on the documentation.
What storage conditions are verified for Hexarelin 5mg?
Follow the actual lot label and product-specific safety and stability documentation. Generic storage tables and studies on another peptide do not establish this product’s shelf life.
Is Hexarelin 5mg intended for human use?
No. This is a research-use listing for in-vitro laboratory work, not human or animal administration. The page provides no dosing, injection or treatment instructions.
US online ordering information
Information for customers reviewing Hexarelin 5mg online from the United States.
This is a research-use listing, not a patient treatment or a finished medicine. Do not use it for human or animal administration. Review the exact formulation and lot-matched documentation, and confirm jurisdiction-specific eligibility before placing any order.
Use the live price and stock display on this page and review the final checkout total. Delivery, tax and return conditions depend on the product and destination; do not assume a delivery date or eligibility from this page alone.
For product or ordering questions, email hello@joinamblehealth.com. Read the Amble terms of service or visit your Amble account.
Reviews
There are no reviews yet.